Neutropenia - Pipeline Review, H2 2020

September 2020 | 137 pages | ID: N536B6E66D9EN
Global Markets Direct

Abstracts

Neutropenia - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Pipeline Review, H2 2020, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.
Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 6, 1, 1, 6, 5, 10 and 1 respectively.
Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
• The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Neutropenia - Overview
Neutropenia - Therapeutics Development
Neutropenia - Therapeutics Assessment
Neutropenia - Companies Involved in Therapeutics Development
Neutropenia - Drug Profiles
Neutropenia - Dormant Projects
Neutropenia - Discontinued Products
Neutropenia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Neutropenia, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Neutropenia - Pipeline by Apotex Inc, H2 2020
Neutropenia - Pipeline by Aprilbio Co Ltd, H2 2020
Neutropenia - Pipeline by BeyondSpring Inc, H2 2020
Neutropenia - Pipeline by Biocon Ltd, H2 2020
Neutropenia - Pipeline by Biocure Technology Inc, H2 2020
Neutropenia - Pipeline by Biosidus SA, H2 2020
Neutropenia - Pipeline by Kashiv BioSciences LLC, H2 2020
Neutropenia - Pipeline by Ligand Pharmaceuticals Inc, H2 2020
Neutropenia - Pipeline by Lupin Ltd, H2 2020
Neutropenia - Pipeline by Merck & Co Inc, H2 2020
Neutropenia - Pipeline by Mycenax Biotech Inc, H2 2020
Neutropenia - Pipeline by Nexgen Biosciences, H2 2020
Neutropenia - Pipeline by Phoenicia Biosciences Inc, H2 2020
Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H2 2020
Neutropenia - Pipeline by Richter Gedeon Nyrt, H2 2020
Neutropenia - Pipeline by Siam Bioscience Co Ltd, H2 2020
Neutropenia - Pipeline by Toko Pharmaceutical Industries Co Ltd, H2 2020
Neutropenia - Dormant Projects, H2 2020
Neutropenia - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neutropenia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Apotex Inc
Aprilbio Co Ltd
BeyondSpring Inc
Biocon Ltd
Biocure Technology Inc
Biosidus SA
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Cleveland BioLabs Inc
CPL Biologicals Pvt Ltd
Dr. Reddy's Laboratories Ltd
Emendo Biotherapeutics
Genova Biotech Company Ltd
Ilkogen Ilac San Ve Tic AS
Kashiv BioSciences LLC
Ligand Pharmaceuticals Inc
Lupin Ltd
Merck & Co Inc
Mycenax Biotech Inc
Nexgen Biosciences
Phoenicia Biosciences Inc
Prolong Pharmaceuticals LLC
Richter Gedeon Nyrt
Siam Bioscience Co Ltd
Toko Pharmaceutical Industries Co Ltd
USV Pvt Ltd
X4 Pharmaceuticals Inc